Stock Scorecard
Stock Summary for Brainstorm Cell Therapeutics Inc (BCLI) - $2.38 as of 1/22/2025 8:27:53 AM EST
Total Score
8 out of 30
Safety Score
21 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for BCLI
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for BCLI
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for BCLI
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for BCLI
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for BCLI (21 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 0 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
Latest News for for BCLI
Financial Details for BCLI
Company Overview |
|
|---|---|
| Ticker | BCLI |
| Company Name | Brainstorm Cell Therapeutics Inc |
| Country | USA |
| Description | Brainstorm Cell Therapeutics Inc., a biotechnology company, is dedicated to the development and commercialization of autologous cell therapies for the treatment of neurodegenerative diseases. The company is headquartered in New York, New York. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 9/30/2024 |
| Next Earnings Date | 3/31/2025 |
Stock Price History |
|
| Last Day Price | 2.38 |
| Price 4 Years Ago | 60.00 |
| Last Day Price Updated | 1/22/2025 8:27:53 AM EST |
| Last Day Volume | 121,494 |
| Average Daily Volume | 103,924 |
| 52-Week High | 11.89 |
| 52-Week Low | 1.05 |
| Last Price to 52 Week Low | 126.67% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 127.55 |
| Sector PE | 41.24 |
| 5-Year Average PE | -38.86 |
| Free Cash Flow Ratio | 79.33 |
| Industry Free Cash Flow Ratio | 16.98 |
| Sector Free Cash Flow Ratio | 27.18 |
| Current Ratio Most Recent Quarter | 0.05 |
| Total Cash Per Share | 0.03 |
| Book Value Per Share Most Recent Quarter | -1.20 |
| Price to Book Ratio | 65.82 |
| Industry Price to Book Ratio | 5.58 |
| Sector Price to Book Ratio | 20.52 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 13.74 |
| Sector Price to Sales Ratio Twelve Trailing Months | 24.40 |
| Analyst Buy Ratings | 0 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 5,703,400 |
| Market Capitalization | 13,574,092 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 3.60% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 29.18% |
| Reported EPS 12 Trailing Months | -3.45 |
| Reported EPS Past Year | -0.59 |
| Reported EPS Prior Year | -1.94 |
| Net Income Twelve Trailing Months | -14,228,000 |
| Net Income Past Year | -17,192,000 |
| Net Income Prior Year | -24,277,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 168,000 |
| Total Cash Past Year | 1,300,000 |
| Total Cash Prior Year | 2,983,000 |
| Net Cash Position Most Recent Quarter | 168,000 |
| Net Cash Position Past Year | 1,300,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 0.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.00 |
| Total Stockholder Equity Past Year | -4,858,000 |
| Total Stockholder Equity Prior Year | -3,015,000 |
| Total Stockholder Equity Most Recent Quarter | -6,057,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -13,013,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.28 |
| Free Cash Flow Past Year | -20,476,000 |
| Free Cash Flow Prior Year | -19,349,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.06 |
| MACD Signal | 0.11 |
| 20-Day Bollinger Lower Band | 0.53 |
| 20-Day Bollinger Middle Band | 2.24 |
| 20-Day Bollinger Upper Band | 3.95 |
| Beta | 0.39 |
| RSI | 47.64 |
| 50-Day SMA | 4.82 |
| 150-Day SMA | 23.22 |
| 200-Day SMA | 30.38 |
System |
|
| Modified | 1/20/2025 7:00:20 PM EST |